Why Compugen Stock Got Slammed Today

Why Compugen Stock Got Slammed Today

Well before market open that day, Jefferies prognosticator Chris Howerton changed his Compugen recommendation to underperform -- sell, in other words -- from his previous hold. While Compugen has had its struggles, the biotech still holds great promise for many, and opinion on its viability can differ considerably. For example, early in January, EF Hutton analyst Tony Butler initiated coverage of the stock with an unhesitant buy recommendation at a comparatively very high price target of $13.